viloxazine   Click here for help

GtoPdb Ligand ID: 11502

Synonyms: Emovit® | ICI-58,834 | ICI-58834 | Qelbree®
Approved drug
viloxazine is an approved drug (FDA (2021))
Compound class: Synthetic organic
Comment: Viloxazine was originally described as a selective norepinephrine reuptake inhibitor (NRI), principally based on its ability to potentiate noradrenergic effects. It also modulates 5-HT (serotonin) activity, via antagonistic activity at 5-HT2B and agonistic activity at 5-HT2C receptors, and it increases extracellular 5-HT levels in the prefrontal cortex (PFC) [4]. Viloxazine's chemical structure is different from conventional tri- or tetra-cyclic antidepressants. The INN stipulates a racemic mixture of enantiomers. We show the structure without specified stereochemistry to represent the mixture. The hydrocholride salt (SPN-812) was progressed by Supernus Pharmaceuticals for attention deficit hyperactivity disorder (ADHD) in children and adults.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 39.72
Molecular weight 237.14
XLogP 1.26
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOc1ccccc1OCC1CNCCO1
Isomeric SMILES CCOc1ccccc1OCC1CNCCO1
InChI InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3
1. Lamb YN. (2021)
Viloxazine: Pediatric First Approval.
Paediatr Drugs, 23 (4): 403-409. [PMID:34036533]
2. Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, O'Neal W, Fava M, Faraone SV, Rubin J. (2021)
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
J Child Adolesc Psychopharmacol, 31 (3): 214-226. [PMID:33600233]
3. Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Cutler AJ, Jones NJ, Findling RL et al.. (2020)
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
Clin Ther, 42 (8): 1452-1466. [PMID:32723670]
4. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. (2020)
New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties.
J Exp Pharmacol, 12: 285-300. [PMID:32943948]